logo

Gamida-Cell Ltd. (GMDA)



Trade GMDA now with
  Date
  Headline
11/14/2022 7:11:19 AM Gamida Cell Q3 Net Loss/shr $0.29 Vs. Loss/shr $0.39 Last Year
9/29/2022 7:11:23 AM Gamida Cell Presents New Long Term Follow-up Data From Omidubicel Phase 3 Trial
9/19/2022 7:08:33 AM Gamida Cell Appoints Abigail Jenkins As President And CEO
8/15/2022 7:31:01 AM Gamida Cell Q2 Net Loss Narrows To $18.6 Mln From $23.6 Mln Last Year
8/10/2022 7:19:02 AM Gamida Cell Doses First Patient In Company-Sponsored Phase 1/2 Study Of NK Cell Therapy Candidate GDA-201
8/1/2022 7:13:22 AM Gamida Cell Announces FDA Acceptance Of BLA For Omidubicel With Priority Review
6/10/2022 7:06:28 AM Gamida Cell Appoints Ivan M. Borrello To Board
6/2/2022 7:08:25 AM Gamida Cell Completes Rolling BLA Submission To FDA For Omidubicel
5/10/2022 7:46:49 AM Gamida Cell Q1 Net Loss $20.2 Mln Vs Net Loss Of $19.2 Mln Prior Year
4/26/2022 7:07:11 AM Gamida Cell Reports FDA Clearance Of IND And Removal Of Clinical Hold For NK Cell Therapy Candidate GDA-201
3/15/2022 7:16:02 AM Gamida Cell FY Net Loss $89.8 Mln Vs Loss Of $61.6 Mln Last Year
11/11/2021 7:13:00 AM Gamida Cell Provides Update On Pre-BLA Meeting With FDA For Omidubicel; Sees Submitting The BLA H1 2022
8/11/2021 7:15:42 AM Gamida Cell Q2 Net Loss $21.3 Mln Vs Net Loss Of $15.1 Mln Prior Year
6/23/2021 7:16:46 AM Gamida Cell Publishes Results Of Phase 3 Study Of Omidubicel In Blood, The Journal Of American Society Of Hematology
5/11/2021 7:14:56 AM Gamida Cell Q1 Net Loss $18.0 Mln Vs. Net Loss $10.6 Mln Last Year
3/9/2021 7:29:26 AM Gamida Cell FY Net Loss $72.7 Mln Vs Loss Of $34.4 Mln Last Year